Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least three years from completion of treatment for Hodgkin's Disease~* Age 18- 35~* Ability to complete self report questionnaires in either English or Spanish~* Willingness of patient, or parent/guardian if patient less than 18 years of age to sign consent to participate in study~* Willingness of patient to sign assent if greater than 7 years of age and less than 18 years~Exclusion Criteria:~* Pregnant or breast feeding~* Tanner Stage 1~* Currently taking cyclosporine, niacin, antiretrovirals, macrolide antibiotic, azole antifungal~* Liver enzymes greater than 1.5 times the upper level of normal~* Creatine Kinase greater than 2 times the upper level of normal~* Use of estrogen containing contraceptive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- A Intervention Arm (Type: EXPERIMENTAL): Escalating dose of simvastatin in subjects who are survivors of Hodgkin Lymphoma

Based on this trial design, predict the completion outcome and termination type (if applicable).